News coverage about Apollo Endosurgery (NASDAQ:APEN) has been trending somewhat positive on Tuesday, Accern reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Apollo Endosurgery earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 45.8686456355087 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Several research analysts have issued reports on the company. Zacks Investment Research upgraded Apollo Endosurgery from a “hold” rating to a “buy” rating and set a $4.75 price target on the stock in a report on Thursday, November 2nd. Northland Securities restated a “buy” rating on shares of Apollo Endosurgery in a report on Friday, October 27th. ValuEngine lowered Apollo Endosurgery from a “sell” rating to a “strong sell” rating in a report on Thursday, August 3rd. Roth Capital assumed coverage on Apollo Endosurgery in a report on Wednesday, August 2nd. They issued a “buy” rating and a $10.00 target price on the stock. Finally, Craig Hallum assumed coverage on Apollo Endosurgery in a report on Monday, July 24th. They issued a “buy” rating and a $11.00 target price on the stock. One analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Apollo Endosurgery presently has a consensus rating of “Buy” and an average price target of $9.44.

Apollo Endosurgery (NASDAQ:APEN) traded down $0.13 during mid-day trading on Tuesday, hitting $4.13. The stock had a trading volume of 18,400 shares, compared to its average volume of 54,451. Apollo Endosurgery has a 52 week low of $3.55 and a 52 week high of $21.88. The company has a debt-to-equity ratio of 0.58, a quick ratio of 2.00 and a current ratio of 2.54.

In related news, VP Bret Schwartzhoff bought 9,500 shares of the company’s stock in a transaction dated Tuesday, November 7th. The shares were bought at an average price of $4.24 per share, for a total transaction of $40,280.00. Following the completion of the acquisition, the vice president now directly owns 15,631 shares of the company’s stock, valued at $66,275.44. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. 74.20% of the stock is owned by company insiders.

ILLEGAL ACTIVITY NOTICE: “Apollo Endosurgery (APEN) Receives Media Impact Score of 0.13” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The correct version of this piece of content can be read at

Apollo Endosurgery Company Profile

Apollo Endosurgery, Inc, formerly Lpath, Inc, is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company’s device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries.

Insider Buying and Selling by Quarter for Apollo Endosurgery (NASDAQ:APEN)

Receive News & Stock Ratings for Apollo Endosurgery Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apollo Endosurgery Inc. and related stocks with our FREE daily email newsletter.